T1792

Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.

Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.

(S,R,S)-AHPC-PEG1-N3 (E3 ligase Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that includes the (S,R,S)-AHPC-based VHL ligand and a 1-unit PEG linker used in PROTAC technology.

(S,R,S)-AHPC-PEG4-N3 (VHL Ligand-Linker Conjugates 5) is a synthesized ligand-linker for E3 ligase-based systems, comprising the (S,R,S)-AHPC VHL ligand and a 4-unit PEG linker, commonly used in PROTAC technology.

(S,R,S)-AHPC-PEG3-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 5) is an E3 ligase ligand-linker conjugate that integrates the (S,R,S)-AHPC-based VHL ligand with a 3-unit PEG linker.

(S,R,S)-AHPC-PEG3-NH2 is a synthetic conjugate composed of the (S,R,S)-AHPC VHL ligand and a 3-unit PEG linker, utilized in PROTAC technology as an E3 ligase ligand-linker.

(S,R,S)-AHPC-PEG2-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate that includes the (S,R,S)-AHPC based VHL ligand and a 2-unit PEG linker used in the synthesis of PROTAC.

(S,R,S)-AHPC-PEG2-NH2 (VHL Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate, incorporating the (S,R,S)-AHPC based VHL ligand and a 2-unit PEG linker used in PROTAC synthesis.

(S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC comprising the (S,R,S)-AHPC based VHL ligand and a 6-unit PEG linker, capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1].

(S,R,S)-AHPC TFA (VHL ligand 1 TFA) (VH032-NH2 TFA) is a VH032-based ligand designed for von Hippel-Lindau (VHL) protein recruitment. This compound can be linked to protein ligands (e.g., BCR-ABL1) using a linker to create PROTACs (e.g., GMB-475), which effectively induce the degradation of BCR-ABL1, demonstrated by an IC50 of 1.11 μM in Ba/F3 cells.

EC089 is a cleavable linker employed in tubulysins and folates conjugates[1].

Regorafenib-D3 is a deuterium labeled Regorafenib. Regorafenib (T1792) is a multi-targeted receptor inhibitor of tyrosine kinase.

Regorafenib-13C-D3 the 13C and deuterated compound of Regorafenib (T1792). Regorafenib has a CAS number of 755037-03-7. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).